PPARG and influenza: (42) initially reported that infection of mice with a sublethal dose of influenza and concurrent treatment of mice with the PPARγ agonist, RGZ, from days 0-6 post-infection, decreased viral titers, neutrophil and monocyte infiltration into the bronchoalveolar lavage fluid, and proinflammatory cytokine production.